Drug intelligence / Profile preview

ABX-265

Development stage: Preclinical
Lead developer: AGILeBiotics
Modality: Small Molecules

Overview

ABX-265 is a small molecule drug developed by AGILeBiotics BV, a biotechnology company based in the Netherlands. The compound is being investigated for the treatment of infectious diseases, with a particular focus on nontuberculous mycobacterium infections. As of May 2025, its highest global R&D status is "Pending," and it remains in preclinical development. Specific details regarding its mechanism of action or molecular targets have not been disclosed publicly[1][2].

Beyond the preview

Go deeper on ABX-265.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABX-265.

Explore the full profile